证券代码：300307 证券简称：慈星股份 公告编号：2023-039 宁波慈星股份有限公司 一、董事会会议召开情况 宁波慈星股份有限公司（以下简称"公司"）第五届董事会第八次会议的会 议通知于 2023 年 11 月 24 日以邮件的方式送达各位董事，会议于 2023 年 11 月 29 日在公司会议室以现场方式召开。会议应出席董事 9 人，实际出席董事 9 人。 会议由孙平范董事长主持，公司监事、高管列席了本次会议。本次会议召集和召 开程序符合《中华人民共和国公司法》等法律法规及《公司章程》有关规定。 会议由董事长孙平范先生主持，审议并形成了以下决议： 二、董事会会议审议情况 1、审议通过《关于作废 2022 年限制性股票激励计划首次授予部分已授予 尚未归属的限制性股票的议案》 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）和公司《公 司 2022 年限制性股票激励计划（草案）》（以下简称"《激励计划》"或"本激励 计划"）的规定，公司 2022 年限制性股票激励计划首次授予的激励对象中，12 名激励对象因离职不再具备激励对象资格；1 名激励对象因不能胜任岗位工作而 导致职务变更，其已获授但 ...

关于作废 2022 年限制性股票激励计划首次授予部分 证券代码：300307 证券简称：慈星股份 公告编号：2023-041 宁波慈星股份有限公司 已授予尚未归属的限制性股票的公告 （三）2022 年 10 月 31 日，公司召开 2022 年第一次临时股东大会审议通过 《关于<宁波慈星股份有限公司 2022 年限制性股票激励计划（草案）>及其摘要 的议案》《关于<宁波慈星股份有限公司 2022 年限制性股票激励计划实施考核管 理办法>的议案》及《关于提请股东大会授权董事会办理 2022 年限制性股票激励 计划相关事宜的议案》等相关议案。公司实施本激励计划获得批准，董事会被授 权确定授予日、在激励对象符合条件时向激励对象授予限制性股票，并办理授予 所必需的全部事宜。 （四）2022 年 11 月 21 日，公司召开第五届董事会第一次会议和第五届监事 会第一次会议，审议通过《关于调整 2022 年限制性股票激励计划首次授予激励 对象名单及授予权益数量的议案》、《关于向激励对象首次授予限制性股票的议 案》。同意确定以 2022 年 11 月 21 日为首次授予日，向符合授予条件的 123 名 激励对象授予 1,9 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥454,952,267.78, representing a year-on-year increase of 4.80%[5] - Net profit attributable to shareholders for Q3 2023 reached ¥21,795,281.34, a significant increase of 68.68% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥9,910,893.22, up by 3,808.00% year-on-year[5] - Basic and diluted earnings per share for Q3 2023 were both ¥0.0279, reflecting a growth of 39.50% compared to the previous year[5] - The net profit for the third quarter of 2023 was CNY 120,344,042.17, an increase from CNY 81,046,790.43 in the same period last year, representing a growth of approximately 48.5%[22] - Operating profit for the third quarter was CNY 124,205,343.77, compared to CNY 82,865,721.23 in the previous year, indicating a year-over-year increase of about 50%[22] - The company reported a total comprehensive income of CNY 121,880,454.87 for the third quarter, compared to CNY 82,593,084.28 in the previous year, reflecting a growth of around 47.5%[22] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥134,977,664.49, showing a substantial increase of 222.15%[5] - The net cash flow from operating activities improved significantly to CNY 134,977,664.49, a 222.15% increase from a negative CNY 110,505,267.68 in the previous year[11] - Cash flow from operating activities generated a net amount of CNY 134,977,664.49, a significant improvement from a negative cash flow of CNY -110,505,267.68 in the same period last year[23] - The net cash flow from investing activities was CNY 53,590,043.05, a recovery from a negative cash flow of CNY -28,923,091.12 in the previous year[23] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥4,655,977,341.26, marking a 5.32% increase from the end of the previous year[5] - The company's total revenue for the current period was CNY 1,720,027,809.67, up from CNY 1,541,845,953.55 in the previous period, representing an increase of about 11.6%[20] - The total liabilities increased to CNY 1,795,923,246.61 from CNY 1,710,346,705.15, an increase of about 5.0%[19] - The company's equity attributable to shareholders rose to CNY 2,896,398,972.71 from CNY 2,750,393,270.02, an increase of approximately 5.3%[19] Receivables and Payables - Accounts receivable decreased by 7.79% from the beginning of the year, amounting to ¥705,967,568.35[10] - The company reported a 28.54% decrease in notes receivable, totaling ¥7,362,916.00[10] - Accounts receivable decreased to CNY 705,967,568.35 from CNY 765,599,251.27, a decline of approximately 7.8%[17] - The company’s total liabilities included accounts payable of CNY 501,578,182.06, reflecting a 9.67% increase from CNY 457,352,000.57[11] Expenses and Investments - Research and development expenses decreased by 21.44% to CNY 36,444,048.25, down from CNY 46,387,650.29 year-on-year[11] - Investment income rose by 52.84% to CNY 12,984,820.55, primarily due to gains from equity transfers of associated companies[11] - The company’s financial expenses decreased significantly by 65.31% to a negative CNY 6,372,470.79, mainly due to the impact of exchange rate fluctuations[11] Cash and Equivalents - Cash and cash equivalents rose to CNY 833,469,155.00 from CNY 556,640,044.45, an increase of about 49.6%[17] - Cash and cash equivalents at the end of the period totaled CNY 355,083,530.26, compared to CNY 134,703,628.99 at the end of the previous year, showing a significant increase[24] - The company reported a significant increase in cash and cash equivalents, totaling CNY 185,209,300.86, a 352.58% rise from a negative CNY 73,327,996.07 in the same period last year[11]

第五届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：300307 证券简称：慈星股份 公告编号：2023-035 宁波慈星股份有限公司 三、备查文件 会议由董事长孙平范先生主持，审议并形成了以下决议： 二、董事会会议审议情况 1、审议通过《关于 2023 年第三季度报告的议案》 本议案以 9 票同意、0 票反对、0 票弃权的表决结果获得通过。 2、审议通过《关于调整公司第五届董事会审计委员会成员的议案》 根据中国证监会发布的《上市公司独立董事管理办法》的相关规定，公司对 第五届董事会审计委员会委员进行调整。公司董事长、总经理孙平范先生不再担 任审计委员会委员，由董事宋甲甲先生担任，与孙科先生（主任委员）、林雪明 先生共同组成公司第五届董事会审计委员会。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于 调整公司第五届董事会审计委员会成员的公告》。 本议案以 9 票同意、0 票反对、0 票弃权的表决结果获得通过。 宁波慈星股份有限公司（以下简称"公司"）第五届董事会第 ...

证券代码：300307 证券简称：慈星股份 公告编号:2023-038 宁波慈星股份有限公司 关于调整公司第五届董事会审计委员会成员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为了保证公司董事会审计委员会规范运作，根据中国证监会发布的《上市公 司独立董事管理办法》第五条"审计委员会成员应当为不在上市公司担任高级管 理人员的董事，其中独立董事应当过半数，并由独立董事中会计专业人士担任召 集人。"的规定，公司调整了第五届董事会审计委员会成员，调整前后的具体情 况如下： | 委员会 | 主任委员 | 其他委员 | | --- | --- | --- | | 审计委员会 | 孙科先生（独立董事） | 宋甲甲先生（非独立董事）、 | | | | 林雪明先生（独立董事） | 调整后的第五届董事会审计委员会委员的任期与第五届董事会任期一致。 特此公告。 宁波慈星股份有限公司 董事会 2023 年 10 月 27 日 一、调整前 委员会 主任委员 其他委员 审计委员会 孙科先生（独立董事） 孙平范先生（非独立董事、总经理）、 林雪明先生（独立董事） 二、调整后 ...

证券代码：300307 证券简称：慈星股份 公告编号:2023-036 宁波慈星股份有限公司 二、监事会会议审议情况 1、审议通过《关于 2023 年第三季度报告的议案》 与会监事一致认为：董事会对《2023 年第三季度报告》的编制和审核的程 序符合法律、法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在虚假记载、误导性陈述或者重大遗 漏。 本议案以 3 票同意、0 票反对、0 票弃权的表决结果获得通过。 三、备查文件 1、第五届监事会第七次会议决议 特此公告。 宁波慈星股份有限公司 监事会 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 宁波慈星股份有限公司（以下简称"公司"）于2023年10月21日以邮件方式 向公司全体监事发出会议通知；2023年10月26日，公司第五届监事会第七次会议 在公司二楼会议室采用现场表决的方式召开，应到监事3人，实到监事3人。会议 由监事会主席俞红建先生主持，公司董事会秘书、证券事务代表列席了本次会议。 本次会议符合《中华 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥1,265,075,541.89, representing a 14.21% increase compared to ¥1,107,722,692.67 in the same period last year[23]. - Net profit attributable to shareholders was ¥95,553,693.59, a 38.21% increase from ¥69,137,105.07 in the previous year[23]. - The net cash flow from operating activities improved significantly to ¥247,109,221.18, compared to a negative cash flow of ¥35,862,783.51 in the same period last year, marking a 789.04% increase[23]. - Basic earnings per share rose to ¥0.12, up 33.33% from ¥0.09 in the previous year[23]. - Total assets at the end of the reporting period were ¥4,637,080,700.37, reflecting a 4.89% increase from ¥4,420,949,370.99 at the end of the previous year[23]. - The net assets attributable to shareholders increased to ¥2,869,878,471.32, a 4.34% rise from ¥2,750,393,270.02 at the end of the previous year[23]. - The company reported a net profit of 7.1 million in the latest financial period, reflecting a significant increase compared to previous periods[60]. - The company reported a significant increase in revenue, achieving a total of 25.66 million yuan for the first half of 2023, representing a year-on-year growth of 58%[63]. - The company reported a net loss of CNY 96,111,446.33, improving from a loss of CNY 191,665,139.92 at the beginning of the year[137]. - The company reported a significant loss in its subsidiary, with a net profit of -763.09 million for the first half of 2023[70]. Revenue and Growth - Revenue from computer knitting machines was 784.27 million yuan, reflecting an 8.25% year-on-year growth, while revenue from one-piece forming computer knitting machines surged by 73.23% to 165.04 million yuan[36]. - The company has set a revenue guidance of 1.4 billion for the next fiscal year, representing a 10% increase from the previous year[61]. - New product launches are expected to contribute an additional 30 million in revenue over the next six months[61]. - The company aims to achieve a revenue growth target of 10% for the full year 2023[156]. - The company has set a revenue target of 6 billion yuan for the full year of 2023, representing a growth target of approximately 10% compared to 2022[163]. Research and Development - Research and development expenses decreased by 13.93% to ¥25,550,942.50 from ¥29,685,497.08 year-on-year[46]. - The company holds 138 invention patents, 333 utility model patents, and 25 design patents, showcasing its strong R&D capabilities[41]. - Research and development expenses accounted for 6.3% of total revenue, indicating a commitment to innovation[156]. - The company plans to expand its market presence through new product launches and technological advancements in the second half of 2023[156]. - The company plans to expand its market presence by investing in new product development and technology innovation, aiming for a 20% increase in R&D expenditure in 2024[163]. Market Position and Strategy - The company is positioned as a leader in the knitting machine industry, actively promoting technological advancements and industry upgrades[39]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[156]. - The company has initiated a strategic acquisition plan targeting complementary businesses to enhance its product offerings and market share, with an estimated budget of 500 million yuan for 2023[163]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of the year[61]. - The company is focusing on expanding its market presence and enhancing product development, although specific new products or technologies were not detailed in the report[67]. Financial Management and Stability - The company has maintained a stable financial position with no significant changes in its investment strategy during the reporting period[66]. - The overall financial health of the company appears robust, with no indications of financial distress or significant liabilities reported[67]. - The company has not reported any expected impairment of principal in entrusted financial management, suggesting effective risk management practices[63]. - The company has no significant changes in its profit structure or sources during the reporting period[47]. - The company has not engaged in any derivative investments or entrusted loans, reflecting a conservative financial approach during this period[64]. Shareholder and Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for this period[4]. - The company confirmed that there were no impacts on earnings per share or net asset value per share due to the share changes[117]. - The company has not reported any new share issuance or repurchase activities during the reporting period[117]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[125]. Risk Factors and Challenges - The company faced significant market risks due to reduced downstream demand and intense competition, leading to a downward pressure on performance[72]. - The company’s overseas orders are primarily settled in USD, exposing it to exchange rate risks without effective hedging measures[72]. - The company’s fixed asset depreciation poses a risk to profitability if revenue does not increase significantly[73]. - The company is actively pursuing market expansion through product promotion activities[72]. Accounting and Compliance - The financial statements are prepared in accordance with the enterprise accounting standards, reflecting the company's financial position and operating results accurately[171]. - The company has established specific accounting policies for financial instruments impairment, fixed asset depreciation, and revenue recognition[170]. - The company ensures that financial liabilities are derecognized when the current obligations are discharged[184]. - The company maintains a focus on fair value measurement and impairment assessment to ensure accurate financial reporting and compliance with accounting standards[186].

北京国枫律师事务所 关于宁波慈星股份有限公司 2022 年限制性股票激励计划预留授予事项的 法律意见书 国枫律证字[2022]AN219-3 号 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层邮编：100005 电话(Tel)：010－66090088/88004488 传真(Fax)：010－66090016 北京国枫律师事务所 关于宁波慈星股份有限公司 1 2022 年限制性股票激励计划预留授予事项的 法律意见书 国枫律证字[2022]AN219-3 号 致：宁波慈星股份有限公司 根据本所与公司签署的《律师服务协议》，本所接受公司的委托，担任公司 本激励计划的专项法律顾问，并已出具《北京国枫律师事务所关于宁波慈星股份 有限公司 2022 年限制性股票激励计划（草案）的法律意见书》（以下简称"《法 律意见书》"）、《北京国枫律师事务所关于宁波慈星股份有限公司 2022 年限制性 股票激励计划首次授予事项的法律意见书》（"《首次授予法律意见书》"）。 依据《公司法》、《证券法》、《管理办法》《监管指南第１号》等有关法律、 法规、规章和规范性文件 ...

证券代码：300307 证券简称：慈星股份 公告编号：2023-029 宁波慈星股份有限公司 第五届董事会第六次会议决议公告 本公司及董事会全体董事保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或者重大遗漏。 董事宋甲甲作为本激励计划预留授予的激励对象，对该议案回避表决。 本议案以 8 票同意、0 票反对、0 票弃权的表决结果获得通过。 经审核，《2023 年半年度报告》及《2023 年半年度报告摘要》符合《公司法》、 《证券法》、《上市公司信息披露管理办法》等相关规定，报告内容真实、准确、 完整地反映了公司 2023 年半年度的经营情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 具体内容详见同日刊登在中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）公告的《2023年半年度报告》及《2023年半年度 报告摘要》。 本议案以 9 票同意、0 票反对、0 票弃权的表决结果获得通过。 二、审议通过了《关于向激励对象预留授予限制性股票的议案》 根据《上市公司股权激励管理办法》、公司《2022 年限制性股票激励计划（草 案）》（以下简称"《激励计划》"或"本激 ...

2、任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票数量累计 不超过公司股本总额的 1%。公司全部有效期内的激励计划所涉及的标的股票总数累计不超 过股权激励计划提交股东大会审议时公司股本总额的 20%。 二、核心骨干人员名单 宁波慈星股份有限公司 2022 年限制性股票激励计划预留授予激励对象名单 （截止预留授予日） 一、预留授予激励对象名单及分配情况 | 姓名 | 职务 | 获授的限制性股 票数量(万股) | 占预留授予权益 总数的比例 | 占目前公司总股 本的比例 | | --- | --- | --- | --- | --- | | 宋甲甲 | 董事 | 100.00 | 33.33% | 0.13% | | 核心骨干人员（34 | 人） | 200.00 | 66.67% | 0.26% | | 合计 | | 300.00 | 100.00% | 0.38% | 注： 1、本计划的激励对象不包括独立董事、监事。 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 胡*群 | 核心骨干人员 | | 2 | 李*洲 | 核心骨干人员 | | 3 | 张* ...